Organogenesis (NASDAQ:ORGO) Stock Price Up 3.9% - Should You Buy?

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) traded up 3.9% during trading on Tuesday . The stock traded as high as $4.86 and last traded at $4.85. 313,614 shares traded hands during mid-day trading, a decline of 72% from the average session volume of 1,124,886 shares. The stock had previously closed at $4.67.

Wall Street Analyst Weigh In

Separately, Morgan Stanley raised their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Organogenesis Stock Performance

The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74. The stock has a market capitalization of $660.14 million, a PE ratio of -87.25 and a beta of 1.79. The firm has a fifty day moving average price of $4.59 and a two-hundred day moving average price of $3.83.

Insider Buying and Selling

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total transaction of $127,500.00. Following the sale, the director now directly owns 166,879 shares in the company, valued at $851,082.90. This represents a 13.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 36.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Soleus Capital Management L.P. lifted its stake in Organogenesis by 5.4% in the 4th quarter. Soleus Capital Management L.P. now owns 12,484,876 shares of the company's stock valued at $39,952,000 after buying an additional 645,000 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company's stock worth $9,443,000 after buying an additional 1,035,120 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Organogenesis by 18.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,789,265 shares of the company's stock valued at $8,925,000 after purchasing an additional 442,772 shares in the last quarter. Renaissance Technologies LLC raised its position in shares of Organogenesis by 31.3% during the fourth quarter. Renaissance Technologies LLC now owns 1,073,500 shares of the company's stock worth $3,435,000 after purchasing an additional 255,600 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Organogenesis by 2.9% during the fourth quarter. Northern Trust Corp now owns 616,089 shares of the company's stock worth $1,971,000 after purchasing an additional 17,196 shares during the period. Institutional investors and hedge funds own 49.57% of the company's stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.